STELLA PHARMA CORPORATION (JP:4888)

:4888

4888

STELLA PHARMA CORPORATION

RESEARCH TOOLSreports

STELLA PHARMA CORPORATION (4888) Price & Analysis

0 Followers

4888 Stock Chart & Stats

¥203.00

-¥14.00(-2.68%)

At close: Jan 08 4:00 PM EST

¥203.00

-¥14.00(-2.68%)

Day’s Range― - ―

52-Week Range¥200.00 - ¥995.00

Previous CloseN/A

Volume163.70K

Average Volume (3M)332.29K

Market Cap

¥22.87B

Enterprise Value¥18.07B

Total Cash (Recent Filing)¥2.85B

Total Debt (Recent Filing)¥727.12M

Price to Earnings (P/E)―

Beta0.93

Next Earnings

Aug 12, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-6.00

Shares Outstanding34,034,100

10 Day Avg. Volume566,500

30 Day Avg. Volume332,290

Financial Highlights & Ratios

PEG Ratio1.10

Price to Book (P/B)3.99

Price to Sales (P/S)13.30

P/FCF Ratio93.66

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue GrowthSustained, large revenue expansion over multiple years indicates meaningful product adoption or market penetration rather than a one-off spike. Durable top-line growth improves the company's ability to scale fixed costs, supports future margin improvement, and provides a foundation for eventual path to profitability if cost structure is managed.

Cash Flow ImprovementTransitioning to positive operating and free cash flow signals improving underlying economics and reduces reliance on external financing. Over the medium term this enhances runway for R&D or commercialization, permits reinvestment, and lowers refinancing risk even if net losses persist while margins are addressed.

Low Leverage / Strong EquityA robust equity position with low leverage provides structural financial flexibility to fund development, absorb losses, and pursue strategic initiatives without near-term solvency pressure. This capital structure supports long-term investment in pipelines or commercialization efforts while limiting interest burden.

Bears Say

Ongoing UnprofitabilityPersistent negative net income and margins are a structural constraint on value creation and equity preservation. Continued losses can erode shareholders' equity over time, force dilutive capital raises, and limit ability to self-fund growth unless the company achieves sustainable margin improvement or profitable product mix.

Weak Cash Conversion Vs EarningsA low conversion of reported earnings into operating cash reflects weak earnings quality and cash-generative capacity relative to accounting losses. This heightens dependency on balance sheet resources or external funding if losses persist and reduces resilience to longer development timelines or unforeseen expense shocks.

Small Workforce / Execution CapacityA small employee base limits internal capacity to scale commercial operations, run parallel R&D programs, and manage complex regulatory submissions. Over the medium term this raises execution risk, increases dependence on partners or contractors, and could slow time-to-market for pipeline assets versus better-resourced peers.

4888 FAQ

What was STELLA PHARMA CORPORATION’s price range in the past 12 months?

STELLA PHARMA CORPORATION lowest stock price was ¥200.00 and its highest was ¥995.00 in the past 12 months.

What is STELLA PHARMA CORPORATION’s market cap?

STELLA PHARMA CORPORATION’s market cap is ¥22.87B.

When is STELLA PHARMA CORPORATION’s upcoming earnings report date?

STELLA PHARMA CORPORATION’s upcoming earnings report date is Aug 12, 2026 which is in 129 days.

How were STELLA PHARMA CORPORATION’s earnings last quarter?

STELLA PHARMA CORPORATION released its earnings results on Feb 12, 2026. The company reported -¥6 earnings per share for the quarter, missing the consensus estimate of N/A by -¥6.

Is STELLA PHARMA CORPORATION overvalued?

According to Wall Street analysts STELLA PHARMA CORPORATION’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does STELLA PHARMA CORPORATION pay dividends?

STELLA PHARMA CORPORATION does not currently pay dividends.

What is STELLA PHARMA CORPORATION’s EPS estimate?

STELLA PHARMA CORPORATION’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does STELLA PHARMA CORPORATION have?

STELLA PHARMA CORPORATION has 34,034,100 shares outstanding.

What happened to STELLA PHARMA CORPORATION’s price movement after its last earnings report?

STELLA PHARMA CORPORATION reported an EPS of -¥6 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.814%.

Which hedge fund is a major shareholder of STELLA PHARMA CORPORATION?

Currently, no hedge funds are holding shares in JP:4888

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

STELLA PHARMA CORPORATION

Stella Pharma Corporation engages in the research, development, manufacturing, and distribution of pharmaceuticals. The company develops drugs for boron neutron capture therapy (BNCT). Its product includes SPM-011, a boron-containing drug for BNCT used for treating head and neck cancer, recurrent malignant glioma and meningioma, and malignant melanoma and angiosarcoma. The company was incorporated in 2007 and is headquartered in Osaka, Japan.